Another study examined the concentration of sEVs’ Aβ1–42, P-S396-tau, and P-T181-tau in 4 groups: (I) individuals with mild to moderate AD, (II) individuals with MCI, (III) individuals who shifted from MCI to AD within the past 36 months, and (IV) controls [59]. This evidence concerns the gene MAPT and Alzheimer disease.